Roozbeh Sharif
Pulmonary Disease · Nederland, TXNPI 1396037008
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by United Therapeutics Corporation at 53.8% of the total. 2025 is the largest year on record at $9,202, 8.8 times the $1,040 reported in 2021. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $70.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$12K
- Sanofi$3K
- Verona Pharma, Inc.$1K
- Hill-rom Company, Inc$875
- AstraZeneca$829
- Inspire Medical Systems, Inc.$825
- plus $4K from 21 others
Across 89 payments — averaging $15,940 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$603K
- Sanofi US Services Inc.$252K
- GSK$215K
- Sanofi$145K
- Astrazeneca UK Limited$110K
- AstraZeneca$76K
- plus $18K from 1 others
What the payments were for
- Consulting fees$11,95752%
- Speaking & faculty fees$8754%
- Travel & lodging$2,19310%
- Food & beverage$7,75434%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 36 | $12,282 |
| Sanofi | 72 | $3,296 |
| Verona Pharma, Inc. | 9 | $1,123 |
| Hill-rom Company, Inc | 1 | $875 |
| AstraZeneca | 31 | $829 |
| Inspire Medical Systems, Inc. | 15 | $825 |
| GSK | 37 | $639 |
| Actelion Pharmaceuticals US, Inc. | 13 | $599 |
| Philips North America LLC | 24 | $396 |
| Electromed, Inc. | 29 | $368 |
| Boehringer Ingelheim | 14 | $281 |
| Baxter Healthcare | 9 | $244 |
| Insmed, Inc. | 8 | $185 |
| Merck | 7 | $168 |
| Globus Medical | 1 | $164 |
| Regeneron Healthcare Solutions, Inc. | 5 | $146 |
| Inogen, Inc. | 4 | $88 |
| AbbVie | 1 | $56 |
| ZOLL Respicardia, Inc. | 1 | $48 |
| Tactile Systems Technology Inc | 1 | $36 |
| Amgen | 1 | $34 |
| Vapotherm Inc | 1 | $27 |
| Advanced Respiratory, Inc | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Itamar Medical Inc | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$11,198
- DUPIXENT$2,161
- Ohtuvayre$1,000
- The Monarch Airway Clearance System$875
- The Vest System Model 105 Home Care$875
- The Vest System 205 Acute Care$875
- Inspire Upper Airway Stimulation System$232
- Excelsius3D Imaging System$164
- Inspire$132
- UPTRAVI$125
- OPSUMIT$125
- BREZTRI$124
How this compares
$22,813 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 177 | $2,268,460 |
| Tyvaso DpiTreprostinil | 65 | $1,609,021 |
| UptraviSelexipag | 36 | $941,959 |
| Dupixent PenDupilumab | 216 | $873,447 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,058 | $743,268 |
| OpsumitMacitentan | 58 | $711,267 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 383 | $262,803 |
| TezspireTezepelumab-Ekko | 24 | $100,138 |
| NucalaMepolizumab | 21 | $97,769 |
| XolairOmalizumab | 12 | $97,723 |
| Breo ElliptaFluticasone/Vilanterol | 183 | $84,079 |
| Fasenra PenBenralizumab | 13 | $76,190 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,117 | $24,199 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $21,674 |
| EliquisApixaban | 25 | $21,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $281 | $2,268,460177 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $599 | $1,653,22694 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $639 | $946,7891,308 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $829 | $383,058483 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Nederland
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.